UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 218

Sortiert nach

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

Gastroenterology (New York, N.Y. 1943), 2018-12, Vol.155 (6), p.1999-2013.e3

2018

Link zum Volltext

Verfügbarkeit prüfen

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

The Lancet (British edition), 2012-12, Vol.380 (9857), p.1909-1915

2012

Link zum Volltext

Verfügbarkeit prüfen

Common variants in the NLRP3 region contribute to Crohn's disease susceptibility

Nature genetics, 2009-01, Vol.41 (1), p.71-76

2009

Link zum Volltext

Verfügbarkeit prüfen

Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis

Gastroenterology (New York, N.Y. 1943), 2010-04, Vol.138 (4), p.1502-1513

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

Hepatology (Baltimore, Md.), 2011-07, Vol.54 (1), p.60-69

2011

Link zum Volltext

Verfügbarkeit prüfen

Common polymorphism in the PNPLA3 /adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease

Journal of hepatology, 2011-10, Vol.55 (4), p.906-912

2011

Link zum Volltext

Verfügbarkeit prüfen

Segmental arterial mediolysis and its mimickers: a case report and review of the literature

European journal of case reports in internal medicine, 2023-10, Vol.10 (11), p.004085-004085

2023

Link zum Volltext

Verfügbarkeit prüfen

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn’s Disease

Clinical gastroenterology and hepatology, 2015-08, Vol.13 (8), p.1480-1486.e3

2015

Link zum Volltext

Verfügbarkeit prüfen

New approach to determine the healthy immune variations by combining clustering methods

Scientific reports, 2021-04, Vol.11 (1), p.8917-8917, Article 8917

2021

Link zum Volltext

Verfügbarkeit prüfen

Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2018-06, Vol.24 (7), p.1428-1439

2018

Link zum Volltext

Verfügbarkeit prüfen

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice

PloS one, 2012, Vol.7 (8), p.e41972-e41972

2012

Link zum Volltext

Verfügbarkeit prüfen

Switching biologics used in inflammatory bowel diseases: how to deal with in practice?

Current opinion in pharmacology, 2020-12, Vol.55, p.82-89

2020

Link zum Volltext

Verfügbarkeit prüfen

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Nature genetics, 2013-09, Vol.45 (9), p.984-994

2013

Link zum Volltext

Verfügbarkeit prüfen

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

Hepatology (Baltimore, Md.), 2014-06, Vol.59 (6), p.2170-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2019-10, Vol.157 (4), p.997-1006.e6

2019

Link zum Volltext

Verfügbarkeit prüfen

A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

Nature genetics, 2015-12, Vol.47 (12), p.1443-1448

2015

Link zum Volltext

Verfügbarkeit prüfen

Glucocorticoids and Inflammation Revisited: The State of the Art

Neuroimmunomodulation, 2002-01, Vol.10 (5), p.247-260

2002

Link zum Volltext

Verfügbarkeit prüfen

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study

Inflammatory bowel diseases, 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(168)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

Common variants in the NLRP3 region contribute to Crohn's disease susceptibility

Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis

Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

Common polymorphism in the PNPLA3 /adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease

Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4

Segmental arterial mediolysis and its mimickers: a case report and review of the literature

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn’s Disease

New approach to determine the healthy immune variations by combining clustering methods

Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice

Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis

Switching biologics used in inflammatory bowel diseases: how to deal with in practice?

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

Glucocorticoids and Inflammation Revisited: The State of the Art

Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC)

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study

Suchergebnisse filtern